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Abstract
Increasing incidence of chronic obstructive pulmonary disease (4th place among all causes of death within the general
population) and overweight, as one factor for progression of respiratory tract pathologies (more than 30% of world population
suffers from overweight) suggest that further study of pathogenetic peculiarities of their combined course and search for new
ways of differential pathogenetic therapy are important nowadays.
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Over the past decade, the understanding of the problem
of chronic obstructive pulmonary disease (COPD) has sig-
nificantly changed, however this pathology still remains an
important medical, social and economic problem. As a matter
of fact, it is a progressive disease which is accompanied not
only by persistent airflow limitation but is also a complex
and heterogeneous condition with marked extrapulmonary
manifestations including disorders of cardiovascular system,
dysfunction of skeletal muscles and diabetes [3, 6, 17]. Ac-
cording to the definition of GOLD-2017: ”COPD is a common
disease that may be prevented and treated, and is character-
ized by persistent respiratory symptoms and obstruction of
airways due to pathologic changes of respiratory passages
and/or alveoli. . . ”.
According to the latest statistics, about 4-22% of adults
aged 40 years and older suffer from COPD [1, 26, 33]. The
world’s prevalence of the disease among men and women is
9.3 and 7.3%, and among smokers its rate is - 26.2 and 2.7%
respectively [17]. A number of multicenter studies conducted
in developed countries, show that the rates of morbidity, in-
validity and mortality double every ten years. According to
the data of World Health Organization (WHO) COPD affects
210 million people and, they estimate that this number will
increase by 30 % in ten years (WHO, 2014).
Chronic obstructive pulmonary disease also results in sig-
nificant social consequences in society. In Ukraine the rate
of primary disablement among adult employable population
due to diseases of respiratory organs became somewhat stable
over the last 5 years and made up 1.1-0.9 per 10 thousand of
working population. Yet annually, on average, 2000 people
are initially recognized as disabled due to chronic obstructive
pulmonary disease. It should be noted that the decrease of
invalidity rate was facilitated by the practical application of
modern approaches based on international recommendations
and national protocols in accordance with the principles of
evidence-based medicine that has significantly improved di-
agnostics, treatment and rehabilitation of patients suffering
from this disease [12, 24, 35].
At the present stage of pulmonology development it has
been established that the disease exacerbation is the most
dangerous stage in COPD course [1, 6, 14, 27, 38]. Disease
exacerbation may occur 1-4 and even more times a year and
considerably expand patient’s treatment costs. Destabiliza-
tion of COPD course, particularly the one requiring in-patient
treatment, is an evidenced factor for life quality impairment of
such patients [7, 14, 39, 48]. Re-hospitalization requires spe-
cial attention as it usually involves higher treatment costs than
primary in-patient treatment [8-10, 12]. Great importance
of disease exacerbation for the prognosis of COPD course
was first reported in GOLD 2011revised edition. This docu-
ment provides the definition of COPD making a point that the
disease exacerbations as well as comorbid pathologies have
a great influence on the severity of its course in individual
patients. Furthermore, GOLD 2011document states that the
number of exacerbation events over the past year was con-
sidered to be one of the principal criteria for possible future
risks in COPD patients. The problem of establishing a definite
diagnosis of COPD exacerbation on admission is also relevant
[7, 9, 25, 26, 51]. Understanding the factors triggering and
proceeding the exacerbation leading to in-patient treatment
is vague, and information about this problem is limited and
quite controversial [1, 2, 44, 46]. Consequently, it is essential
to find other reliable markers of potential threat of COPD
exacerbations, especially the severe ones.
Until recently, leading was the point of view that the sever-
ity of bronchial obstruction alone influences the frequency
of exacerbations [30, 35, 40]. The correlation between the
frequency of exacerbations and the severity of symptoms is
exhibited in conclusions of advanced research works. How-
ever, these two factors are not completely independent and
patients with moderate limitation of respiratory function may
also suffer from frequent exacerbations [3-5, 7, 10].
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Currently more and more attention is paid to the study
of possible role of extra-pulmonary factors associated with
the increase of COPD exacerbation risks [1, 2, 45, 53]. In
recent years, extrapulmonary COPD effects have been widely
discussed, as they exacerbate the disease course in individual
patients and are essential part of ”etiological pathogenetic
circle”. That is why they must be always taken into account
in clinical management of patients [4, 14, 23, 29, 47]. Rec-
ognizing the presence of such manifestations is clinically
important and may contribute to better understanding of the
disease development. At the same time, the likelihood of
systemic reactions is variable in different COPD stages and
the frequency of their combined course increases with the
disease progression. It has been shown that the development
of extra-pulmonary COPD effects has an important clinical
and prognostic value [5-7, 50].
One of these extra-pulmonary effects, having a negative
influence on the course of chronic obstructive pulmonary dis-
ease, is overweight which is a risk factor for the development
and rapid progression of a number of chronic diseases, in-
cluding pathology of the respiratory tract (L.M.Niu, 2012;
N.Hizawa, 2013; K.F. Rabe, 2014). A number of studies have
revealed that the phenotype of COPD patient with marked
overweight is associated with frequent exacerbations, accel-
erated decrease in pulmonary function, decreased strenuous
activity and quality of patient’s life, as well as increased eco-
nomic costs [11, 19, 20, 29].
The fact that weight reduction leads to the decrease in the
degree of clinical manifestations of COPD may prove the role
of overweight in the development and rapid progression of
respiratory pathology [43, 45, 49].
It has been established that the prevalence rate of chronic
obstructive pulmonary disease and overweight is on the in-
crease throughout the world. According to analysis and sys-
tematic reviews in 28 countries of the world the incidence
of the pathology among adult population is approximately
10% (Y.I. Feshchenko et al., 2017). As reported by the WHO,
more than 30% of world’s population suffers from overweight,
among them 16.8% - women, 14% - men. In Ukraine this
index is 30% of adult population (in most European countries
- 9-20%). At the same time, WHO predicts that nearly 700
million adults will have suffered from overweight by 2020;
consequently, it is expected that these two states will combine
with increasing frequency [2, 16]. The problem of excess body
weight has lately moved beyond the limits of endocrinology
and nowadays has turned into an acute general-medical and
social problem. By the scale and incidence rate this problem
has obtained the character of global epidemics [41, 42].
A number of epidemiologic investigations show that over-
weight generally occurs at early stages of COPD. It leads
to a number of dysfunctions of various organs and systems,
including the respiratory one. Alteration of respiratory mus-
cle contractility is observed in such patients, resulting in the
decrease of maximal inspiratory pressure, chest rise during
breathing and decrease in lung volume. Chest rise reduction
leads to compensatory lengthening of inspiration and expi-
ration resulting in the development of nonspecific bronchial
hyperreactivity. It is proved that respiratory muscles in over-
weight people work two times harder to maintain adequate
ventilation as compared to people with healthy body weight
[29, 37, 41].
Scientists contend that overweight leads to the combina-
tion of both variants of pulmonary dysfunction, namely the
restriction (decrease in lung volume) and obstruction (narrow-
ing of distal airways) [43, 52]. Literature sources describe
the influence of overweight on respiratory function, that in-
volves: the decrease in diameter of peripheral airways causing
bronchial hyperreactivity, limitation of the air flow from the
lungs due to the reduction of lung volume (forced expiratory
volume (FEV1) and forced lung capacity) [20, 35, 39]. More-
over, it was suggested that overweight is associated with sys-
temic inflammation in chronic obstructive pulmonary disease
having unfavourable influence on its course: alteration of res-
piratory function, increased activity of inflammatory processes
due to immune changes associated with biological activity of
fatty tissue as additional source of pro-inflammatory cytokines
resulting in frequent exacerbations and rapid progression of
the disease [1, 50].
Reduced physical activity due to shortness of breath and
long-term use of systemic glucocorticosteroids to prevent ex-
acerbation events at late stages of COPD progression are the
possible mechanisms for increased risk of overweight devel-
opment among patients suffering from chronic obstructive
pulmonary disease (M. C. McCormack, 2015). Compulsory
restriction of physical activity is the most common complaint
among COPD patients, as it negatively influences their quality
of life. Accumulation of fatty tissue is accompanied by the
COPD-specific loss of muscle mass that has a negative influ-
ence on exercise tolerance completing the circle of sedentary
lifestyle and excessive weight [3, 5, 8, 13].
In turn, body weight and sedentary lifestyle influence the
usual COPD course (Sutherland E., 2004) causing exacerba-
tions at early stages of the disease (Hurst J.R. et al., 2010),
which have an important short- and long-term influence on
patients with this pathology (Feshchenko Yu.I. et al., 2016).
Long-term study conducted by Cotes J.E. (1996) showed that
gaining only 1 kilo leads to the decrease of FEV1level by
approximately 17.6 ml, and forced lung capacity - by 21.4 ml
in 8 patients and did not depend on their age.
COPD is a chronic inflammation of airways, and special
importance in its pathogenesis belongs to cellular and molec-
ular mechanisms. Pro-inflammatory cytokines are the key
components of bronchial inflammation progression [15, 16,
21, 22]. A number of scientific investigations were conducted
with the aim to study their role in the development and course
of chronic obstructive pulmonary disease in Ukraine and other
countries. A new phenomenon has been revealed: overweight
is accompanied by pimelitis which proceeds with infiltration
of fatty tissue by immunocompetent cells. Since inflamma-
tory reaction occurs in well-vascularized and innervate tissue,
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thus, due to this some systemic symptoms should be expected
[34]. Currently it has been established that fatty tissue pro-
duces a lot of hormone-like substances, mediators, cytokines
and chemokines which are commonly called adipokines or
adipocytokines. They act both on local and system levels [5,
9, 11, 14]. In order to determine the role of inflammatory pro-
cess as a specific COPD factor, it’s necessary to differentiate
between localized inflammation, which occurs directly within
the tissues of bronchopulmonary complex, and systemic in-
flammation, which manifests itself by specific disorders and
causes systemic reactions [19, 23, 27, 34]. Migration and acti-
vation of immunocompetent blood cells in tissues of bronchi
and lungs, production and breakdown of matrix proteins, fi-
brosis and structural remodeling of bronchial and pulmonary
walls are characteristic for localized inflammation. Activated
cells in chronic inflammation are the source of a great num-
ber of inflammatory mediators. Localization and intensity of
chronic inflammation, its nature and peculiarities of trigger-
ing mechanisms determine the specific nature of pathological
process, character of clinical signs and symptoms, COPD pro-
gression rate, and are also the markers of adequate therapy
and prognosis [16, 18, 28-32].
Of the adipokines described in recent years, particular
attention is given to inflammatory markers, one of which is IL-
6, which is produced by activated monocytes, macrophages,
endothelial cells, fibroblasts, activated T-cells, as well as by
a number of cells that are not immunocytes, and is one of
the most active transmitters involved in the realization of
immune reaction and inflammatory response [38, 50]. Equally
important is the role of IL-6 in the regulation of synthesis of
acute-phase proteins which promote inflammation. C-reactive
protein (CRP) is one example of such acute-phase proteins.
It instantly reacts to inflammation by elevating its level both
in blood and other body fluids; moreover, this elevation is
directly proportional to the intensity of inflammatory lesion
(Casas JP et al., 2008). The levels of inflammatory proteins
in systemic circulation are elevated even in stable COPD
course, including the levels of CRP and IL-6, while inverse
relationship is noticed between the levels of inflammatory
mediators and FEV1, CRP, IL-6, and imbalance between pro-
inflammatory and anti-inflammatory cytokines in favor of the
former ones [13, 16, 34].
Imbalance between pro-inflammatory and anti-inflammatory
cytokines in blood serum of patients becomes particularly no-
table in events of COPD exacerbations and is directly related
to the peculiarity and severity of disease exacerbation course
[34-36].
Recently reported studies show that high levels of inflam-
matory markers in patients with COPD may be associated
with marked mortality rates among patients, their frequent
hospitalization and quite rapid progression of this pathology,
that’s why this index may be used as prognostic marker partic-
ularly for patients with chronic obstructive pulmonary disease,
chronic bronchitis and bronchial asthma (Savelikhina I.O.,
2013; Melnyk O.P., 2014; Popadynets I.R., 2014), especially
in combination with other proinflammatory markers.
Consolidating the data from various scientific sources,
COPD should be considered as a complex heterogeneous dis-
ease, in the course of which the most important and the most
”tragic” event is its exacerbation that quite often may be fatal
at terminal stages of the disease. Potential predictors of COPD
exacerbations (especially those requiring in-patient treatment)
include: clinical signs (for example, shortness of breath),
anamnestic data (primarily the history of past exacerbations),
changes in functional characteristics of respiratory tract, over-
weight (that significantly intensifies the course of disease), as
well as a number of socioeconomic markers. Consequently,
COPD is considered to be a complex pathology, and in order
to prognosticate its course it is necessary to study not only
the anamnesis and damage of bronchopulmonary apparatus,
but also identify other system changes in the patient’s body
and define the levels of local inflammatory markers taking
into account various phenotypes, particularly excessive body
weight of patients.
Conclusions
The study of correlation between the frequency of COPD ex-
acerbations and changes in IL-6 and C-reactive protein levels
in patients with overweight will certainly make it possible
to quickly, easy and accurately establish the process activity,
make reasonable prognosis and choose adequate and individ-
ualized anticipatory treatment plan for every patient that is
of great importance nowadays and still will be significant for
improving the quality of life of such patients.
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